Tic disorder is a common childhood neuropsychiatric disorder characterized by motor tics and/or vocal tics. The pathogenesis of tic disorder is related to the increase of local dopamine level in the brain. Aripiprazole is a new third-generation atypical antipsychotic drug and one of the effective treat-ments for tic disorder. However, the use of aripiprazole is off-label administration in the treatment of tic disorder, and the therapeutic window is not yet clear. In addition, there are large individual variabilities in pharmacokinetics. In order to improve the efficacy and safety of aripiprazole in the treatment of tic disorders in children, it is of great significance to investigate the pharmacokinetics of aripiprazole and to explore the mechanism of individual differences. This article reviews the current study status and sig-nificance of the pharmacokinetics for aripiprazole in the treatment of children with tic disorder.

1. Deeb W, Malaty IA, Mathews CA. Tourette disorder andother tic disorders[J]. Handb Clin Neurol, 2019, 165: 123-153. DOI: 10.1016/B978-0-444-64012-3.00008-3.

2. Pedersen JH, Skytthe A, Bybjerg-Grauholm J, et al. Concordance and comorbidities among monozy-gotic twins with tic disorders[J]. J Psychiatr Res, 2022, 146: 297-303. DOI: 10.1016/j.jpsychires.2021.11.019.

3. 杨静, 王平平, 俞丹, 等. 中国抽动障碍患者西药治疗随机对照试验证据现状与趋势分析[J]. 中国药物应用与监测, 2018, 15(3): 181-185. [Yang J, Wang PP, Yu Dan, et al. Trends and quality assessment of randomized controlled trials of western medicine for tic disorders in China[J]. Chinese Journal of Drug Application and Monitoring, 2018, 15(3): 181-185]. DOI: 1672-8157(2018)03-0181-05.

4. 翟倩, 丰雷, 张国富. 阿立哌唑在儿童抽动障碍中的应用研究进展[J].中国全科医学, 2019, 22(14): 1717-1721, 1725. [Zhai Q, Feng L, Zhang GF. Research progress of aripiprazole in children with tic disorder[J]. Chinese General Practice, 2019, 22(14): 1717-1721, 1725]. DOI: 10.12114/j.issn.1007-9572.2019.00.001.

5. Ribeiro ELA, de Mendonça Lima T, Vieira MEB, et al. Efficacy and safety of aripiprazole for the treat-ment of schizophrenia: an overview of systematic reviews[J]. Eur J Clin Pharmacol, 2018, 74(10): 1215-1233.  DOI: 10.1007/s00228-018-2498-1.

6. Janik P, Szejko N. Aripiprazole in treatment of gilles de la tourette syndrome -new therapeutic op-tion[J]. Neurol Neurochir Pol, 2018, 52(1): 84-87. DOI: 10.1016/j.pjnns. 2017.10.015.

7. Bachmann CJ, Rieger-Gies A, Heinzel-Gutenbrunner M, et al. Large variability of aripiprazole and de-hydroaripiprazole serum concentrations in adolescent patients with schizophrenia[J]. Ther Drug Monit, 2008, 30(4): 462-466. DOI: 10.1097/FTD.0b013e318178e18d.

8. 刘茂昌,刘智胜. 儿童抽动障碍药物治疗研究现状[J]. 中华实用儿科临床杂志, 2020, 35(12): 948-951. [Liu MC, Liu ZS. Current research status on pharmacological treatment for children with tic disorsers[J]. Chinese Journal of Applied Clinical Pediatrics, 2020, 35(12): 948-951]. DOI: 10.3760/cma.j.cn101070-20190329-00260.

9. 吴金丽. 阿立哌唑的临床应用[J]. 医学信息, 2018, 31(14): 42-45. [Wu JL. Clinical application of aripipra-zole[J]. Medical Information, 2018, 31(14): 42-45]. DOI: 10.3969/j.issn.1006-1959.2018.14.014.

10.Sallee F, Kohegyi E, Zhao J, et al. Randomized, double-blind, placebo-controlled trial demonstrates the efficacy and safety of oral aripiprazole for the treatment of Tourette's disorder in children and adolescents[J]. J Child Adolesc Psychopharmacol, 2017, 27(9): 771-781. DOI: 10.1089/cap.2016.0026.

11.张建华, 康冰瑶, 李丹, 等. 药物治疗儿童抽动障碍的系统评价再评价[J]. 中国药房, 2021, 32(21): 2647-2654. [Zhang JH, Kang BY, Li D, et al. Overview of the systematic review of drug treatment for tic disorders in children[J]. China Pharmacy, 2021, 32(21): 2647-2654]. DOI: 10.6039/j.issn. 1001-0408.2021.21.15.

12.Zheng W, Li XB, Xiang YQ, et al. Aripiprazole for Tourette's syndrome: a systermatic review and me-ta-analysis[J]. Hum Psychopharmacol, 2016,31(1):11-18. DOI: 10.1002/hup.2498.

13.Jovanović M, Vučićević K, Miljković B. Understanding variability in the pharmacokinetics of atypical anti-psychotics-focus on clozapine, olanzapine and aripiprazole population models[J]. Drug Metab Rev, 2020, 52(1): 1-18. DOI: 10.1080/03602532.2020.1717517.

14.Rygaard K, Linnet K, Banner J, et al. Concentrations of aripiprazole and dehydroaripiprazole in hair segments from deceased individuals with mental disorders[J]. Forensic Sci Int, 2020, 317: 110523. DOI: 10.1016/j.forsciint.2020.110523.

15.Mauri MC, Paletta S, Di Pace C, et al. Clinical pharmacokinetics of atypical antipsychotics: an update[J]. Clin Pharmacokinet, 2018, 57(12): 1493-1528. DOI: 10.1007/s40262-018-0664-3.

16.Belmonte C, Ochoa D, Román M, et al. Evaluation of the relationship between pharmacokinetics and the safety of aripiprazole and its cardiovascular effects in healthy volunteers[J]. J Clin Psychopharma-col, 2016, 36(6): 608. DOI: 10.1097/JCP.0000000000000577.

17.Findling RL, Kauffman R, Sallee FR, et al. An open-label study of aripiprazole: pharmacokinetics, toler-ability, and effectiveness in children and adolescents with conduct disorder[J]. J Child Adolesc Psy-chopharmacol, 2009, 19(4): 431-439. DOI: 10.1089/cap.2008.0111.

18.Findling RL, Kauffman RE, Sallee FR, et al. Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders：an open-label, dose-escalation study[J]. J Clin Psycho-pharmacol, 2008, 28(4): 441-446. DOI: 10.1097/JCP.0b013e31817dd520.

19.Hard ML, Wehr AY, Sadler BM, et al. Population pharmacokinetic analysis and model-based simula-tions of aripiprazole for a 1-day initiation regimen for the long-acting antipsychotic aripiprazole lauroxil[J]. Eur J Drug Metab Pharmacokinet, 2018, 43(4): 461-469. DOI: 10.1007/s13318-018-0488-4.

20.Koller D, Belmonte C, Lubomirov R, et al. Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects[J]. J Psychopharmacol, 2018, 32(11): 1212-1222. DOI: 10.1177/02698811187 98605.

21.Tveito M, Molden E, Høiseth G, et al. Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status[J]. Eur J Clin Pharmacol, 2020, 76(1): 41-49. DOI: 10.1007/s00228-019-02768-0.

22.Gaedigk A, Sangkuhl K, Whirl-Carrillo M, et al. Prediction of CYP2D6 phenotype from genotype across world populations[J]. Genet Med, 2017, 19(1): 69-76. DOI: 10.1038/gim.2016.80.

23.Zhang X, Liu C, Zhou S, et al. Influence of CYP2D6 gene polymorphisms on the pharmacokinetics of aripiprazole in healthy Chinese subjects[J]. Pharmacogenomics, 2021, 22(4): 213-223. DOI: 10.2217/pgs-2020-0134.

24.Zhang XD, Xiang Q, Zhao X, et al. Association between aripiprazole pharmacokinetics and CYP2D6 phenotypes: A systematic review and meta-analysis[J]. J Clin Pharm Ther, 2019, 44(2): 163-173. DOI: 10.1111/jcpt.12780.

25.Kneller LA, Zubiaur P, Koller D, et al. Infuence of CYP2D6 phenotypes on the pharmacokinetics of ari-piprazole and dehydro aripiprazole using a physiologically based pharmacokinetic approach[J]. Clin Pharmacokinet, 2021, 60(12): 1569-1582. DOI: 10.1007/s40262-021-01041-x.

26.Belmonte C, Ochoa D, Román M, et al. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 polymor-phisms on pharmacokinetics and safety of aripiprazole in healthy volunteers[J]. Basic Clin Pharmacol Toxicol, 2018, 122(6): 596-605. DOI: 10.1111/bcpt.12960.

27.Rafaniello C, Sessa M, Bernardi FF, et al. The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions[J]. Pharmacogenomics J, 2017, 18(3): 422-430. DOI: 10.1038/tpj.2017.38.

28.Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017[J]. Pharmacopsychiatry, 2018, 51(1-02): 9-62. DOI: 10.1055/s-0043-116492.

29.师亚玲, 方志远, 李茁, 等. 万古霉素首次监测与个体化给药后血药浓度未达标的影响因素分析[J]. 中国药师, 2020, 23(2): 307-310. [Shi YL, Fang ZY, Li Z, et al. Analysis of the related factors in vancomycin concentrations not up to standard after first monitoring and individualized administration [J]. China Pharmacist, 2020, 23(2): 307-310]. DOI: 10.3969/j.issn.1008-049X.2020. 02.022.